These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24005812)

  • 1. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
    Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S
    Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.
    Hayakawa N; Matsumoto K; Sato A; Sakamoto H; Ezaki T; Maeda T; Ninomiya A; Nakamura S
    Int Urol Nephrol; 2014 Jun; 46(6):1123-9. PubMed ID: 24356920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
    Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T
    Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
    Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
    Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
    Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.
    Minato A; Fujimoto N; Kubo T; Harada S; Akasaka S; Matsumoto T
    Med Oncol; 2012 Dec; 29(4):2895-900. PubMed ID: 22323054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
    Garcia JA; Weinberg V; Small EJ
    Clin Prostate Cancer; 2005 Sep; 4(2):113-7. PubMed ID: 16197612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.
    Kitamura T
    Int J Urol; 2001 Feb; 8(2):33-6. PubMed ID: 11240822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
    Hirayama Y; Ito Y; Kanamaru T; Sonoda T; Aoyama M; Nakamura N; Kawamura M
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):485-7. PubMed ID: 21403461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
    Smaletz O; Galsky M; Scher HI; DeLaCruz A; Slovin SF; Morris MJ; Solit DB; Davar U; Schwartz L; Kelly WK
    Ann Oncol; 2003 Oct; 14(10):1518-24. PubMed ID: 14504052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.